Asthma is currently treated with inhalator glucocorticoids, long-acting beta agonists, leukotriene receptor antagonists, and long-acting antimuscarinic agents advancing to biologic therapies, particularly for the high-T2 (characterized by the subpopulation of CD4+ T cells—Th2 cells secreting the IL-4, IL-5, IL-13) resistant asthma phenotype. Here, CD4 is linked to asthma.